RxDoctor Payments Data

Mary Newsome

Family · Cambridge, OHNPI 1215441308

Payments from drug & device makers

$2,439in general payments, 2019–2025

Across 109 payments — averaging $22.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$822
  • AstraZeneca$541
  • Lilly USA, LLC$347
  • Sanofi-aventis U.S. LLC$125
  • Edwards Lifesciences$115
  • Bayer$114
  • plus $375 from 7 others

What the payments were for

  • Food & beverage$2,439100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,439 in reported general payments places this provider in the 85th percentile of 6,812 family providers in Ohio.

See all family providers in Ohio

Medicare billing

Part B allowed, 2024
$14,542
Medicare patients
152
Services billed
653

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide76$135,959
FarxigaDapagliflozin Propanediol44$45,301
EliquisApixaban19$20,526
Breztri AerosphereBudesonide/Glycopyr/Formoterol17$11,625
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$10,351
Lantus SolostarInsulin Glargine,hum.Rec.Anlog23$2,698
Gabapentin104$1,577
Albuterol Sulfate HfaAlbuterol Sulfate77$1,300
Duloxetine Hcl42$944
Omeprazole91$860
Baclofen36$766
Atorvastatin Calcium167$623
Lisinopril121$594
Levothyroxine Sodium105$563
Doxycycline Hyclate74$537

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$822$135,95976 claims
AstraZenecaFarxiga, Breztri Aerosphere$541$56,92661 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 6,812 family providers in Ohio.

Other family in Cambridge

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →